Literature DB >> 1527260

Transpulmonary gradient of type III procollagen peptides: acute effects of cardio-pulmonary bypass.

N K Harrison1, G J Laurent, T W Evans.   

Abstract

Type III procollagen N-peptides (PIIINPs) are believed to be released in stoichiometric amounts as type III collagen molecules are secreted from cells. We hypothesized that if the human lung actively produces type III collagen a detectable transpulmonary gradient in PIIINPs would exist in normal individuals that might be altered following a pulmonary insult. PIIINPs were therefore measured by radioimmunoassay in serum taken simultaneously from the pulmonary artery (PA) and left ventricle/aorta (LV) in 11 patients undergoing routine cardiac catheterisation. Mean PIIINP levels +/- SEM in LV were 66.8 +/- 5.4 micrograms.ml-1 and 59.9 +/- 4.1 micrograms.ml-1 in PA (p less than 0.04). In 6 patients, repeat measurements taken 4 h after cardiopulmonary bypass revealed a significant fall in PA values to 43.8 +/- 2.6 micrograms.ml-1 (p less than 0.001) and abolition of the transpulmonary gradient. These results suggest the adult human lung actively synthesis type III collagen and that, in the short term, cardiopulmonary bypass inhibits this process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527260     DOI: 10.1007/bf01706477

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  22 in total

1.  Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting.

Authors:  M J Rennie; R H Edwards; D Halliday; D E Matthews; S L Wolman; D J Millward
Journal:  Clin Sci (Lond)       Date:  1982-12       Impact factor: 6.124

2.  Variability in lung collagen amounts after prolonged support of acute respiratory failure.

Authors:  J F Collins; J D Smith; J J Coalson; W G Johanson
Journal:  Chest       Date:  1984-05       Impact factor: 9.410

3.  Heterogeneity of the antigens related to the aminoterminal propeptide of type III procollagen in human serum.

Authors:  O Niemelä; L Risteli; E A Sotaniemi; J Risteli
Journal:  Clin Chim Acta       Date:  1982-09-01       Impact factor: 3.786

4.  Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome.

Authors:  P Entzian; A Hückstädt; H Kreipe; J Barth
Journal:  Am Rev Respir Dis       Date:  1990-11

5.  Adult respiratory distress syndrome following cardiopulmonary bypass: incidence and prediction.

Authors:  M Messent; K Sullivan; B F Keogh; C J Morgan; T W Evans
Journal:  Anaesthesia       Date:  1992-03       Impact factor: 6.955

6.  Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration.

Authors:  C M Black; A McWhirter; N K Harrison; J M Kirk; G J Laurent
Journal:  Br J Rheumatol       Date:  1989-04

7.  Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study.

Authors:  K D Bentsen; K Hørslev-Petersen; P Junker; E Juhl; I Lorenzen
Journal:  Liver       Date:  1987-04

8.  Type I collagen content is increased in lungs of patients with adult respiratory distress syndrome.

Authors:  J A Last; A D Siefkin; K M Reiser
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

9.  Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments.

Authors:  H Rohde; I Langer; T Krieg; R Timpl
Journal:  Coll Relat Res       Date:  1983-09

10.  Type III procollagen N-terminal peptides in experimental pulmonary fibrosis and human respiratory diseases.

Authors:  Y Watanabe; K Yamaki; I Yamakawa; K Takagi; T Satake
Journal:  Eur J Respir Dis       Date:  1985-07
View more
  1 in total

1.  Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Wenyaw Chan; Basant Arya; Yimin Ge; Anita Deswal; Biykem Bozkurt; Adaani Frost; Mark Entman
Journal:  JACC Heart Fail       Date:  2014-07-09       Impact factor: 12.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.